Iron deficiency anemia Medical Services in China

Iron deficiency anemia (IDA) is a common hematologic disorder characterized by insufficient iron stores to support normal red blood cell production, resulting in microcytic, hypochromic anemia. It arises when iron demand exceeds supply—either due to inadequate dietary intake, impaired gastrointestinal absorption, chronic blood loss (e.g., menorrhagia, gastrointestinal bleeding from ulcers or colorectal lesions), or increased physiological requirements (e.g., pregnancy, infancy, adolescence). Pathogenically, iron depletion progresses through three stages: first, depletion of storage iron (ferritin ↓); second, reduction in serum iron and transferrin saturation with compensatory rise in total iron-binding capacity (TIBC); and third, frank anemia with low hemoglobin, low mean corpuscular volume (MCV), and low mean corpuscular hemoglobin (MCH). Without intervention, IDA impairs oxygen delivery, mitochondrial function, and cellular energetics—particularly affecting high-demand tissues like skeletal muscle, brain, and myocardium. Epidemiologically, IDA affects over 1.2 billion people globally, making it the most prevalent nutritional deficiency worldwide. Prevalence is highest among women of childbearing age (15–25% in non-pregnant, up to 40% in pregnant women), young children (20–30% under age 5), adolescents, and older adults with comorbid gastrointestinal disease. Key risk factors include vegetarian/vegan diets low in heme iron, chronic NSAID use, celiac disease, Helicobacter pylori infection, gastric bypass surgery, heavy menstrual bleeding, frequent blood donation, and undiagnosed gastrointestinal malignancy. Beyond hematologic parameters, IDA significantly diminishes quality of life: patients commonly report profound fatigue, reduced exercise tolerance, cognitive fog, irritability, pica (craving for ice, clay, or starch), restless legs syndrome, brittle nails (koilonychia), and pallor. Untreated, it contributes to impaired work productivity, school performance deficits in children, postpartum complications, heart failure exacerbation in susceptible individuals, and increased susceptibility to infections due to compromised immune cell function. Early diagnosis—via complete blood count, ferritin (gold-standard marker, though acute-phase reactant), serum iron, TIBC, and reticulocyte hemoglobin content (Ret-He)—is critical to guide targeted therapy and uncover underlying etiology, especially occult GI bleeding in adults over 50. Management must therefore integrate iron repletion with rigorous diagnostic evaluation to address root causes, ensuring sustainable recovery and preventing recurrence.

Iron deficiency anemia (IDA) is the most prevalent form of anemia worldwide, characterized by insufficient iron to support adequate hemoglobin synthesis, resulting in microcytic, hypochromic red blood cells and impaired oxygen delivery. Its pathogenesis stems from an imbalance between iron supply and demand—either due to inadequate intake, diminished absorption, increased physiological requirements, or chronic blood loss.

Common causes include chronic gastrointestinal (GI) blood loss, which accounts for the majority of adult-onset IDA cases in non-menstruating individuals. Sources encompass peptic ulcer disease, gastritis (especially associated with *Helicobacter pylori* infection or NSAID use), colorectal neoplasms (e.g., adenocarcinoma, polyps), angiodysplasia, celiac disease–induced mucosal injury, and inflammatory bowel disease (IBD). In women of childbearing age, menorrhagia—often secondary to uterine fibroids, adenomyosis, or coagulopathies—is the predominant cause. Other significant contributors include frequent blood donation, postpartum hemorrhage, and iatrogenic phlebotomy in hospitalized patients.

Triggers are acute or subacute events that unmask or exacerbate underlying iron depletion. These include pregnancy (with its 500–1000 mg total iron demand increase), rapid growth spurts in infants and adolescents, initiation of intense endurance training (which increases iron turnover and may induce foot-strike hemolysis), and acute GI bleeding episodes (e.g., Mallory-Weiss tear, variceal rupture). Acute inflammation can also transiently lower serum iron and hepcidin-mediated iron sequestration, mimicking or compounding true iron deficiency.

Risk factors span multiple domains. Demographically, infants aged 6–24 months are highly vulnerable due to rapid expansion of red cell mass and low iron stores at birth—especially if exclusively breastfed beyond six months without iron supplementation. Toddlers consuming excessive cow’s milk (>24 oz/day) face dual risks: milk-induced occult GI blood loss and poor dietary iron intake. Adolescents, particularly girls experiencing menarche and growth acceleration, exhibit heightened susceptibility. Pregnant individuals require ~27 mg/day of elemental iron; inadequate prenatal supplementation significantly elevates IDA risk. Older adults (>65 years) face multifactorial risks including atrophic gastritis (reducing acid-dependent iron solubilization), chronic GI malignancy, polypharmacy (e.g., PPIs impairing iron absorption), and functional decline limiting dietary diversity.

Genetic factors play a modulatory rather than primary role. While classic IDA is not inherited, several monogenic disorders predispose to iron malabsorption or chronic blood loss. Mutations in *TMPRSS6* cause iron-refractory iron deficiency anemia (IRIDA), characterized by inappropriately elevated hepcidin leading to blocked intestinal iron absorption despite systemic deficiency. Hereditary hemorrhagic telangiectasia (HHT; *ENG*, *ACVRL1*, *SMAD4* mutations) results in recurrent mucocutaneous and GI bleeding. Celiac disease (strongly associated with HLA-DQ2/DQ8 haplotypes) induces villous atrophy and impaired iron uptake. Rare variants in *DCYTB* (duodenal cytochrome b) or *SLC11A2* (DMT1) may reduce duodenal iron reduction or transport efficiency, though clinical penetrance is variable.

Environmental and socioeconomic determinants substantially influence IDA prevalence. Low-income populations often experience diets deficient in bioavailable heme iron (found in meat, fish, poultry) and rich in inhibitors like phytates (whole grains, legumes) and polyphenols (tea, coffee), which chelate non-heme iron. Food insecurity, limited access to fortified foods or supplements, and inadequate maternal nutrition during pregnancy perpetuate intergenerational iron deficits. Occupational exposures—such as chronic aspirin or NSAID use among healthcare workers or laborers—contribute to GI mucosal injury. Geographic factors matter: endemic *H. pylori* infection and parasitic infestations (e.g., *Ancylostoma duodenale*, *Necator americanus*) in tropical and subtropical regions drive substantial blood loss and iron depletion. Urban air pollution and chronic low-grade inflammation may also dysregulate hepcidin expression, indirectly impairing iron homeostasis. Finally, cultural dietary practices—e.g., vegetarianism without careful planning for iron enhancers (vitamin C-rich foods) and avoidance of inhibitors during meals—can elevate risk, particularly when combined with other vulnerabilities.

Iron deficiency anemia (IDA) is the most prevalent form of anemia worldwide, characterized by insufficient iron to support adequate hemoglobin synthesis, resulting in microcytic, hypochromic red blood cells and impaired oxygen delivery. Its clinical presentation spans a spectrum from subtle, nonspecific early manifestations to overt systemic symptoms and potentially serious complications if left untreated.

Early symptoms are often insidious and easily overlooked, particularly in otherwise healthy individuals or those with chronic comorbidities. Fatigue—described as persistent, disproportionate tiredness unrelieved by rest—is nearly universal and frequently the first complaint. Patients may report diminished exercise tolerance, mild shortness of breath on exertion (dyspnea on exertion), and reduced concentration or mental fogginess, reflecting early cerebral hypoxia and altered neurotransmitter metabolism. Pallor, especially of the conjunctivae, palmar creases, and nail beds, may be detectable on physical examination before subjective symptoms escalate. Mild tachycardia at rest or with minimal activity may occur due to compensatory cardiac output augmentation. These early signs reflect adaptive physiological responses rather than end-organ damage and often prompt evaluation only when they interfere with daily function or are incidentally noted during routine assessment.

Typical symptoms emerge as hemoglobin declines further (typically <10 g/dL in adults) and tissue oxygenation becomes significantly compromised. Profound fatigue progresses to exhaustion and profound weakness. Dyspnea becomes more pronounced, occurring even at rest in severe cases. Palpitations and orthostatic lightheadedness reflect increased cardiac demand and reduced cerebral perfusion pressure. Headache, dizziness, and vertigo are common, attributable to cerebral vasodilation and impaired autoregulation. Patients frequently describe cold intolerance and paresthesias in extremities, linked to peripheral vasoconstriction and altered nerve conduction. Glossitis (inflammatory tongue swelling and smooth, depapillated appearance), angular cheilitis (fissuring at oral commissures), and koilonychia (spoon-shaped, brittle nails) represent classic epithelial manifestations of chronic iron depletion, reflecting impaired mitochondrial enzyme function and keratinocyte differentiation. Pica—the compulsive ingestion of non-nutritive substances such as ice (pagophagia), clay, or starch—is a highly specific behavioral correlate of IDA, thought to arise from dopaminergic dysregulation in the basal ganglia.

Accompanying symptoms reflect multisystem involvement beyond hematopoietic and neurologic domains. Gastrointestinal disturbances include anorexia, epigastric discomfort, and occasionally mild constipation or diarrhea; these may precede or coexist with the underlying cause (e.g., occult gastrointestinal bleeding). In women of childbearing age, menorrhagia is both a common cause and an accompanying symptom, often reported as prolonged, heavy, or clot-heavy menses. Restless legs syndrome (RLS)—characterized by an irresistible urge to move the legs, worsening at rest and in the evening—is strongly associated with IDA and improves with iron repletion, implicating striatal iron-dependent dopamine synthesis. Cognitive deficits may manifest as impaired working memory, slowed processing speed, and decreased attention span, particularly notable in children and adolescents where IDA can adversely affect academic performance and neurodevelopment.

Complications arise from prolonged, untreated IDA and reflect cumulative hypoxic stress and iron-dependent enzymatic dysfunction. High-output heart failure may develop in susceptible individuals, presenting with exertional dyspnea, paroxysmal nocturnal dyspnea, orthopnea, and peripheral edema—driven by chronic tachycardia, increased stroke volume, and eventual myocardial remodeling. Chronic IDA predisposes to recurrent infections due to impaired neutrophil and lymphocyte function, including diminished oxidative burst and T-cell proliferation. In pregnancy, IDA increases risks of preterm birth, low birth weight, and postpartum depression. Children with chronic IDA face long-term neurocognitive sequelae, including persistent deficits in language acquisition, fine motor skills, and executive function, even after correction of hemoglobin. Severe IDA can precipitate angina in patients with underlying coronary artery disease and exacerbate pulmonary hypertension in those with chronic lung disease.

Diagnosis relies on a tiered laboratory approach. Initial screening includes complete blood count (CBC), revealing microcytosis (low MCV <80 fL), hypochromia (low MCH <27 pg, low MCHC <32 g/dL), and anemia (hemoglobin <13 g/dL in adult males, <12 g/dL in adult females, adjusted for altitude and pregnancy). Peripheral blood smear shows characteristic microcytic, hypochromic erythrocytes, anisocytosis, and poikilocytosis. Confirmatory testing requires serum ferritin—the most sensitive and specific indicator of iron stores—with levels <15 ng/mL diagnostic of absolute iron deficiency; levels 15–30 ng/mL suggest functional deficiency in inflammatory states. Additional supportive markers include low serum iron, elevated total iron-binding capacity (TIBC), low transferrin saturation (<16%), and elevated soluble transferrin receptor (sTfR) or sTfR/log ferritin index. Reticulocyte hemoglobin content (Ret-He) <29 pg provides real-time assessment of iron availability for erythropoiesis. Endoscopic evaluation (upper and lower GI endoscopy) is mandatory in adult men and postmenopausal women to exclude occult malignancy or other sources of chronic blood loss.

Differential diagnosis must distinguish IDA from other microcytic anemias. Thalassemia trait typically presents with disproportionately high RBC count, normal or elevated hemoglobin, and elevated HbA2 (>3.5%) on hemoglobin electrophoresis; ferritin remains normal. Anemia of chronic disease (ACD) features normocytic or mildly microcytic anemia with elevated or normal ferritin (due to hepcidin-mediated iron sequestration), low serum iron, low TIBC, and low transferrin saturation—distinguishing it from IDA’s low ferritin and high TIBC. Sideroblastic anemias show ringed sideroblasts on bone marrow iron stain and may involve mitochondrial dysfunction or genetic mutations; serum ferritin is often elevated. Lead poisoning causes basophilic stippling on peripheral smear, elevated blood lead levels, and abdominal colic; iron studies may mimic IDA but ferritin is usually normal or elevated. Rare causes include copper deficiency (causing myeloneuropathy and microcytosis) and congenital atransferrinemia. Comprehensive evaluation integrates clinical context, iron studies, hemoglobin analysis, and, when indicated, bone marrow examination or genetic testing.

Iron deficiency anemia (IDA) is the most prevalent form of anemia worldwide, characterized by insufficient iron stores to support adequate hemoglobin synthesis, resulting in microcytic, hypochromic red blood cells and impaired oxygen delivery. In the Department of Hematology, management is stratified according to etiology, severity, comorbidities, and patient-specific factors—including age, gastrointestinal (GI) anatomy, absorption capacity, and tolerance to oral therapy. A comprehensive approach integrates conservative measures, pharmacologic intervention, targeted surgical evaluation, and long-term monitoring.

Conservative treatment forms the cornerstone of IDA management, particularly in mild-to-moderate cases without acute hemorrhage or high-risk features. It begins with rigorous diagnostic workup: complete blood count (CBC), peripheral blood smear, serum ferritin (the most specific indicator of iron stores), serum iron, total iron-binding capacity (TIBC), transferrin saturation (TSAT), and soluble transferrin receptor (sTfR). In adults—especially men and postmenopausal women—occult GI blood loss must be excluded via fecal immunochemical testing (FIT) and endoscopic evaluation (esophagogastroduodenoscopy and colonoscopy). Nutritional counseling is integral: patients are advised to increase dietary heme iron intake (e.g., lean red meat, poultry, fish) while avoiding concurrent ingestion of iron inhibitors such as calcium supplements, antacids, proton pump inhibitors (PPIs), tea, coffee, and phytate-rich foods. Vitamin C–rich foods (e.g., citrus fruits, bell peppers) should be consumed with iron-rich meals to enhance non-heme iron absorption. Lifestyle modifications include menstrual assessment in premenopausal women (e.g., evaluation for menorrhagia, uterine fibroids, or coagulopathies) and cessation of NSAID use where appropriate.

Pharmacologic therapy is initiated based on ferritin levels and clinical severity. Oral iron supplementation remains first-line for uncomplicated IDA. Ferrous sulfate (325 mg tablet = 65 mg elemental iron), ferrous fumarate (325 mg = 100 mg elemental iron), and ferrous gluconate (325 mg = 36 mg elemental iron) are commonly prescribed. Dosing regimens have evolved: recent evidence supports alternate-day dosing (e.g., 100 mg elemental iron every other morning on an empty stomach) to improve absorption and reduce gastrointestinal side effects (nausea, constipation, abdominal cramping) without compromising efficacy. Treatment duration extends beyond hemoglobin normalization—typically 3–6 months—to replenish hepatic and bone marrow iron stores, confirmed by follow-up ferritin >50 µg/L and TSAT >20%. Intravenous (IV) iron is indicated when oral therapy fails (e.g., persistent anemia despite 4–6 weeks of adherence), intolerance, malabsorption syndromes (e.g., celiac disease, post-bariatric surgery), chronic inflammatory conditions (where hepcidin-mediated blockade limits oral absorption), or severe anemia (Hb <9 g/dL) with symptomatic burden (e.g., angina, heart failure, profound fatigue). Modern IV formulations—including ferric carboxymaltose (FCM), ferric derisomaltose (FDI), and low-molecular-weight iron dextran—are administered as single or split infusions under hemodynamic monitoring. FCM allows rapid repletion (up to 1000 mg in ≤15 minutes) and has demonstrated superior safety over older dextran-based products, with minimal risk of anaphylaxis (<0.1%).

Surgical intervention is not a primary treatment for IDA itself but is essential when IDA serves as a sentinel sign of underlying structural pathology. In the hematology setting, close collaboration with gastroenterology, gynecology, and general surgery is mandatory. Indications for surgery include: (1) endoscopically confirmed bleeding lesions refractory to medical therapy (e.g., angiodysplasia amenable to argon plasma coagulation or endoscopic band ligation); (2) resectable GI malignancies (e.g., colon cancer, gastric adenocarcinoma); (3) surgically correctable gynecologic causes (e.g., hysterectomy for refractory menorrhagia due to large fibroids or adenomyosis); and (4) vascular malformations or hereditary hemorrhagic telangiectasia (HHT)-related epistaxis requiring septodermoplasty or laser ablation. Laparoscopic and robotic-assisted techniques minimize perioperative morbidity and accelerate recovery. Preoperative optimization includes IV iron repletion to avoid unnecessary allogeneic transfusion, reduce postoperative complications, and shorten hospital stay.

Treatment advantages in China reflect robust infrastructure, innovation, and integration. Chinese hematology centers—particularly tier-3 hospitals in Beijing, Shanghai, Guangzhou, and Chengdu—offer rapid access to high-sensitivity ferritin assays, mass spectrometry–based iron metabolism panels, and AI-enhanced endoscopic detection of subtle mucosal bleeding. Domestic production of high-purity IV iron (e.g., CosmoFer®-equivalent ferric carboxymaltose manufactured by Jiangsu Hengrui) ensures cost-effectiveness and supply chain resilience. National Clinical Guidelines for Iron Deficiency Anemia (2023 edition) standardize diagnostic thresholds (e.g., ferritin <30 µg/L diagnostic in adults; <15 µg/L in children) and endorse early IV iron in high-risk populations. Telehematology platforms facilitate longitudinal monitoring, medication adherence tracking, and remote nutritional coaching—critical for rural patients. Moreover, China’s large-scale epidemiologic databases (e.g., China Kadoorie Biobank) inform precision risk stratification, identifying genetic variants (e.g., TMPRSS6 polymorphisms) associated with iron-refractory IDA.

Recovery advice emphasizes sustainability and prevention. Patients should undergo repeat CBC and ferritin at 4 weeks after initiating therapy, then every 3 months until stores normalize. Lifelong surveillance is recommended for those with chronic blood loss (e.g., hereditary hemorrhagic telangiectasia, inflammatory bowel disease) or malabsorption. Dietary education must be culturally tailored: encouraging traditional iron-rich foods like pig liver, duck blood curd, black fungus, and fortified soy sauce, while advising moderation of tea consumption during meals. Women of childbearing age should receive preconception counseling regarding iron prophylaxis (e.g., 30–60 mg elemental iron daily starting 3 months prior to conception). All patients must understand that symptom resolution (e.g., improved energy, cognition, exercise tolerance) often precedes laboratory normalization by 2–4 weeks—and that premature discontinuation of therapy risks relapse. Finally, psychosocial support is vital: chronic IDA correlates with depression, reduced quality of life, and workplace impairment; multidisciplinary rehabilitation—including graded aerobic activity and cognitive behavioral strategies—improves functional outcomes. With systematic, patient-centered care, >95% of IDA cases achieve full hematologic recovery within 6 months, underscoring the importance of timely diagnosis, individualized therapy, and proactive long-term stewardship.